BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Pfizer (PFE) and BioNTech (BNTX) lose bid to appeal a High Court ruling that issued Moderna (MRNA) a COVID-19 vaccine patent ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...

Johnson & Johnson JNJ announced strong second-quarter results earlier this month. The drug and medical device giant beat ...